BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

And Cobenfy's approval comes after two other recent setbacks in the late-stage schizophrenia pipeline; namely, the FDA’s rejection of Minerva Neurosciences’ application for roluperidone and ...

Cobenfy: A Key Growth Driver One of the most significant developments for Bristol-Myers Squibb has been the launch and performance of Cobenfy, its new drug for schizophrenia.

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The Food and Drug Administration yesterday released a safety notice announcing a software patch is available to address ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...